Goal 2: Reduce Human Disease

Pulmonary Vascular Diseases

Does treatment with spironolactone improve outcomes in patients with pulmonary arterial hypertension (and/or pulmonary hypertension associated with diffuse parenchymal lung disease or COPD)?

 

Spironolactone has been shown beneficial in CHF and many of the same mechanisms are at plan in RV failure from pulmonary hypertension.

 

Again, no clear evidence whether this is a useful treatment or not, and no evidence to guide treatment.

Tags (Keywords associated with the idea)

Voting

2 net votes
2 up votes
0 down votes
Active
Idea No. 1175